Evidence map›Paper›PMID 35281046›Full record

ArticleFrontiers in immunology2022

Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine.

Floriane Gallais, Pierre Gantner, Delphine Planas, Morgane Solis, Timothée Bruel, Florian Pierre, Eric Soulier, Paola Rossolillo, Slim Fourati, Jean Sibilia and 2 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Floriane GallaisCHU de Strasbourg, Laboratoire de Virologie, Strasbourg, France.
Pierre GantnerCHU de Strasbourg, Laboratoire de Virologie, Strasbourg, France.
Delphine PlanasVirus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France.
Morgane SolisCHU de Strasbourg, Laboratoire de Virologie, Strasbourg, France.
Timothée BruelVirus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France.
Florian PierreCHU de Strasbourg, Laboratoire de Virologie, Strasbourg, France.
Eric SoulierCHU de Strasbourg, Laboratoire de Virologie, Strasbourg, France.
Paola RossolilloInstitut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Unité Mixte de Recherche (UMR) 7104, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch, France.
Slim FouratiDepartment of Virology, Hôpital Henri Mondor, Créteil, France.
Jean SibiliaCHU de Strasbourg, Département de Rhumathologie, Strasbourg, France.
Olivier SchwartzVirus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France.
Samira Fafi-KremerCHU de Strasbourg, Laboratoire de Virologie, Strasbourg, France.
Immuno-Rhumathologie moléculaireInserm · FRInstitut de Recherche Vaccinale · FRInstitut de Virologie · FRCentre National de la Recherche Scientifique · FRUniversité de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: SARS-CoV-2 breakthrough infections after complete vaccination are increasing whereas their determinants remain uncharacterized. Methods: We analyzed two cases of post-vaccination SARS-CoV-2 infections by α and β variants, respectively. For each participant both humoral (binding and neutralizing antibodies) and cellular (activation markers and cytokine expression) immune responses were characterized longitudinally. Results: The first participant (P1) was infected by an α variant and displayed an extended and short period of viral excretion and symptom. Analysis of cellular and humoral response 72 h post-symptom onset revealed that P1 failed at developing neutralizing antibodies and a potent CD4 memory response (lack of SARS-CoV-2 specific CD4 Conclusions: An analysis of cellular and humoral response suggests two possible mechanisms of breakthrough infection: a poor immune response to vaccine and viral evasion to neutralizing antibodies.

Indexed as

AdultAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineBreakthrough InfectionsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCOVID-19COVID-19 VaccinesFemaleHumansImmune EvasionMiddle AgedSARS-CoV-2VaccinationAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 Vaccinesbreakthrough infectionimmune evasionSARS-CoV-2vaccinevariant of concern

Identifiers

PMID35281046
PMCPMC8905643
OpenAlexW4213168234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.